---
title: "Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns"
date: "2025-02-10 12:22:47"
summary: "Love Employee/iStock via Getty Images Arrowhead Pharmaceuticals (NASDAQ:ARWR) is working on RNA interference [RNAi] and now has a “Targeted RNAi Molecule” or [TRiM] for short. This way, ARWR can theoretically target cardiometabolic, pulmonary, and metabolic diseases. Moreover, last year, they also reached some important milestones that should act as tailwinds..."
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1981445243/image_1981445243.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![una llave inglesa, unos alicates y un destornillador y un ADN de hélice](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1981445243/image_1981445243.jpg?io=getty-c-w750) 



Love Employee/iStock via Getty Images





Arrowhead Pharmaceuticals (NASDAQ:[ARWR](https://seekingalpha.com/symbol/ARWR "Arrowhead Pharmaceuticals, Inc.")) is working on RNA interference [RNAi] and now has a “Targeted RNAi Molecule” or [TRiM] for short. This way, ARWR can theoretically target cardiometabolic, pulmonary, and metabolic diseases. Moreover, last year, they also reached some important milestones that should act as tailwinds for

[seekalpha_articles](https://seekingalpha.com/article/4756554-cautious-on-arrowhead-pharmaceuticals-fda-nda-acceptance-due-to-valuation-concerns)
